News
Back to News

FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation

Dr. Richard Pazdur

Richard Pazdur, MD

The FDA has approved defibrotide sodium (Defitelio) as a treatment for severe hepatic veno-occlusive disease (VOD) with associated kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT), based on data from the collection of 3 studies.

Across the single-arm trials, two of which were prospective and one that was an expanded access study, 38% to 45% of patients were alive at 100 days following HSCT. The current 100-day survival rates with best supportive care following HSCT for patients with severe hepatic VOD are 21% to 31%, according to the FDA.

Severe hepatic VOD occurs in approximately 2% of patients treated with HSCT and has an 84% mortality rate. The approval for defibrotide followed a priority review by the FDA that was granted after a rolling submission that was allowed under a fast track designation. The PDUFA deadline was March 31, 2016. Click here to read the full article at OncLive.com




Back to News


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By